Zydus Lifesciences Limited — Others, 16-07-2025: Shareholders meeting

Zydus Lifesciences reports robust FY25 consolidated financial results, with total income rising 19% to 23,240 Cr and EBITDA increasing 31% to 7,058.5 Cr. Net profit grew 23% to 4,745.1 Cr, supported by a strong net cash position of 4,883.6 Cr. The company is actively expanding its portfolio, acquiring a 50% stake in Sterling Biotech for specialized products and entering the MedTech space with a majority stake in Amplitude Surgical SA. Strategic R&D investment of 1,855.5 Cr continues to drive innovation and new product launches. The Board has proposed a final dividend of 11/- per share.